The role of the genomic mutation signature and tumor mutation burden on relapse risk prediction in head and neck squamous cell carcinoma after concurrent chemoradiotherapy

참고문헌 (41)

1. Carvalho, A. L., "Trends in incidence and prognosis for head and neck cancer in the United States: a site‐specific analysis of the SEER database", Int. J. Cancer, 114, pp.806~816 (2005)
2. Grégoire, V., "Squamous cell carcinoma of the head and neck : EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann. Oncol, 21, pp.v184~v186 (2010)
3. Sun, X. -S., "Debio 1143 and high-dose cisplatin chemoradiotherapy in highrisk locoregionally advanced squamous cell carcinoma of the head and neck : a double-blind, multicentre, randomised, phase 2 study", Lancet Oncol, 21, pp.1173~1187 (2020)
4. Leemans, C. R, "The molecular biology of head and neck cancer", Nat. Rev. Cancer, 11, pp.9~22 (2011)
5. Bernier, J., "Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer", N. Engl. J. Med, 350, pp.1945~1952 (2004)
6. Cooper, J. S., "Long-term follow-up of the RTOG 9501", intergroup phase III trial : postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck, 2012, pp.84, 1198~1205
7. Cooper, J. S., "Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck", N. Engl. J. Med, 350, pp.1937~1944 (2004)
8. Fietkau, R., "Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck : Results of the German phase III trial ARO 96–3", J. Clin. Oncol, 24, pp.5507~5507 (2006)
9. Johansen, S., "Patterns of local-regional recurrence after conformal and intensity-modulated radiotherapy for head and neck cancer", Radiat. Oncol, 12, pp.1~8 (2017)
10. Troeltzsch, M., "What factors are associated with regional recurrence after operative treatment of oral squamous cell carcinoma?", J. Oral. Maxillofac. Surg, 76, pp.2650~2659 (2018)
11. Toustrup, K., "Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck", Radiother. Oncol, 102, pp.122~129 (2012)
12. Eschrich, S. A., "A gene expression model of intrinsic tumor radiosensitivity : prediction of response and prognosis after chemoradiation", Int. J. Radiat. Oncol. Biol. Phys, 75, pp.489~496 (2009)
13. Liao, C. -T., "Whole-exome sequencing identifies biosignatures that predict adverse survival outcomes in surgically treated patients with oral cavity squamous cell carcinoma", Oral. Oncol, 122, pp.105547~ (2021)
14. Fan, W. -L., "Prognostic Genetic Biomarkers Based on Oncogenic Signaling Pathways for Outcome Prediction in Patients with Oral Cavity Squamous Cell Carcinoma", Cancers(Basel), 13, pp.2709~ (2021)
15. Moreira, A., "Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery", ESMO Open, 6, pp.100178~ (2021)
16. P Basourakos, S., "Combination platinum-based and DNA damage responsetargeting cancer therapy : evolution and future directions", Curr. Med. Chem, 24, pp.1586~1606 (2017)
17. Kiwerska, K., "DNA repair in cancer initiation, progression, and therapy —a double-edged sword", J. Appl. Genet, 60, pp.329~334 (2019)
18. Lans, H., "ATP-dependent chromatin remodeling in the DNA-damage response", Epigenet. Chromatin, 5, pp.1~14 (2012)
19. Wang, H. -C., "Consistent administration of cetuximab is associated with favorable outcomes in recurrent", metastatic head and neck squamous cell carcinoma in an endemic carcinogen exposure area : a retrospective observational study, 2020, pp.8, e9862~
20. Frampton, G. M., "Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing", Nat. Biotechnol, 31, pp.1023~1031 (2013)
21. Johnson, D. E., "Head and neck squamous cell carcinoma", Nat Rev Dis Primers, 6, pp.92~ (2020)
22. Network, C. G. A., "Comprehensive genomic characterization of head and neck squamous cell carcinomas", Nature, 517, pp.576~ (2015)
23. Canning, M., "Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy", Front. Cell Dev. Biol, 7, pp.52~ (2019)
24. Leemans, C. R, "The molecular landscape of head and neck cancer", Nat. Rev. Cancer, 18, pp.269~282 (2018)
25. Gaździcka, J., "Epigenetic modifications in head and neck cancer", Biochem. Genet, 58, pp.213~244 (2020)
26. Mascolo, M., "Epigenetic disregulation in oral cancer", Int. J. Mol. Sci, 13, pp.2331~2353 (2012)
27. Kumar, M., "Inhibition of histone acetyltransferase function radiosensitizes CREBBP", EP300 mutants via repression of homologous recombination, potentially targeting a gain of function, 2021, pp.12, 1~16
28. Consortium, A. P. G., "AACR Project GENIE: powering precision medicine through an international consortium", Cancer Disco, 7, pp.818~831 (2017)
29. Burtness, B., "Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-048) : a randomised, open-label, phase 3 study", Lancet, 394, pp.1915~1928 (2019)
30. Ferris, R. L., "Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck : 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression", Oral. Oncol, 81, pp.45~51 (2018)
31. Solomon, B., "Head and neck squamous cell carcinoma : Genomics and emerging biomarkers for immunomodulatory cancer treatments", Semin. Cancer Biol, 52, pp.228~240 (2018)
32. Oliva, M., "Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma", Ann. Oncol, 30, pp.57~67 (2019)
33. Addeo, A., "TMB or not TMB as a biomarker: That is the question", Crit. Rev. Oncol. Hematol, 163, pp.103374~ (2021)
34. Chan, T. A., "Development of tumor mutation burden as an immunotherapy biomarker : utility for the oncology clinic", Ann. Oncol, 30, pp.44~56 (2019)
35. Ding, H., "Tumor mutational burden and prognosis across pan-cancers", Ann. Oncol, 29, pp.viii16~viii17 (2018)
36. Ito, T., "Regulation of cellular senescence by polycomb chromatin modifiers through distinct DNA damage-and histone methylation-dependent pathways", Cell Rep, 22, pp.3480~3492 (2018)
37. Kim, E., "Phosphorylation of EZH2 activates STAT3 signaling via STAT3methylation and promotes tumorigenicity of glioblastoma stem-like cells", Cancer Cell, 23, pp.839~852 (2013)
38. Wu, J., "Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cells", Sci. Rep, 7, pp.1~13 (2017)
39. Li, L. J., "β‐Elemene radiosensitizes lung cancer A549 cells by enhancing DNA damage and inhibiting DNA repair", Phytother. Res, 25, pp.1095~1097 (2011)
40. Coqueret, O., "Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21 WAF1", CIP1, J. Biol. Chem, pp.2000, 275[DOI]
41. Sitko, J. C., "SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage", Cell Signal, 20, pp.2221~2230 (2008)

관련 논문AI추천